JPY 610.0
(-0.65%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -1.1 Billion JPY | -40.34% |
2022 | -786.99 Million JPY | -31.38% |
2021 | -599.02 Million JPY | -44.97% |
2020 | -413.21 Million JPY | 50.87% |
2019 | -841 Million JPY | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -219 Million JPY | -6.96% |
2023 Q2 | -211.36 Million JPY | 49.93% |
2023 Q1 | -422.12 Million JPY | -87.82% |
2023 Q4 | -204.74 Million JPY | 23.09% |
2023 Q3 | -266.22 Million JPY | -25.96% |
2023 FY | -1.1 Billion JPY | -40.34% |
2022 Q3 | -199 Million JPY | -22.24% |
2022 FY | -786.99 Million JPY | -31.38% |
2022 Q4 | -224.74 Million JPY | -12.94% |
2022 Q2 | -162.79 Million JPY | 0.0% |
2021 FY | -599.02 Million JPY | -44.97% |
2020 FY | -413.21 Million JPY | 50.87% |
2019 FY | -841 Million JPY | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 81.18 Billion JPY | 101.36% |
Astellas Pharma Inc. | 17.04 Billion JPY | 106.48% |
Chugai Pharmaceutical Co., Ltd. | 325.47 Billion JPY | 100.339% |
Ono Pharmaceutical Co., Ltd. | 127.97 Billion JPY | 100.863% |
Santen Pharmaceutical Co., Ltd. | 26.64 Billion JPY | 104.146% |
JCR Pharmaceuticals Co., Ltd. | 5.5 Billion JPY | 120.056% |
Daiichi Sankyo Company, Limited | 200.73 Billion JPY | 100.55% |
Otsuka Holdings Co., Ltd. | 121.61 Billion JPY | 100.908% |